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Copyright © 2008 JCBN 2008 This is an open access article distributed under the terms of the Creative Commons Attribution License, which per- mits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Isoflavones, an important class of flavonoids that are
found at extremely high levels in soy have gained consider-
able attention for their potential in improving risk factors for
cardiovascular disease. The three major extensively studied
soy isoflavones are genistein, daidzein and glycetein [1].
The US Food and Drug Administration (FDA) in 1999 and
the American Heart Association in (AHA) in 2000
recommended that soy protein containing foods may be
protective against cardiovascular disease (CVD) [2, 3]. But
in 2006, the AHA analysis suggests that the use of isofla-
vone supplements in food or pills is not recommended [4].
However, strong scientific evidence has been emerging
recently related to the nutritional benefits of flavonoids
including isoflavones [5]. A recent study of flavonoid intake
and the risk of ischemic stroke and CVD mortality suggest
that high intake of flavonoids may be associated with
decreased risk of ischemic stroke and possibly reduced CVD
mortality [6]. In another study in U.S adults the intake of
dietary flavonoids including daidzein and genistein was
inversely associated with serum levels of C-reactive protein
(CRP) a biomarker for chronic inflammation and a sensitive
risk factor for CVD [7]. It is reported that genistein upregu-
lates the gene expression of antioxidant enzyme manganese-
superoxide dismutase (Mn SOD) and antioxidant metal-
lothionein expression [8, 9]. Increased expression of catalase
in human hepatoma cells by daidzein has also been recently
reported [10]. In vitro and in vivo studies have demonstrated
that soy isoflavones genistein and daidzein may be useful
antigenotoxic antioxidants by scavenging free radicals,
inhibiting lipid peroxidation and protecting against oxida-
tive DNA damage [11]. Recent reports reveal that genistein
exhibit vascular protective effects by targeting on important
signaling molecules in vascular endothelial cells including
upregulation of human endothelial nitric oxide synthase
[12]. Why is the inconsistency in clinical study reports of
flavonoids? Key questions that need to be addressed include
the gut bacterial metabolism of daidzein and its metabolites
especially equol since it has longer half-life and greater
biological activity, including superior antioxidant activity
[13]. Recently the vasorelaxant and antioxidant activity of
equal have been reported in carotid and cerebral arteries
[14]. Using microarray analysis it has been found that
isoflavone treatment in subjects who have the capacity to
produce equal differentially affects gene expression as
compared to non-producers, supporting the significance of
equal production [15]. Thus the link between daidzein
metabolizing phenotypes and the interaction of its metabo-
lites at the gene level need to be further probed. And finally
nutrigenomic and nutrigenetic aspects of isoflavones on
CVD have to be studied in detail before any final verdict on
the cardioprotective effects of these bioactive nutrients.
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